MAPT and Alzheimer disease: These exosomes, isolated from AD patients, showed significantly higher levels of Aβ1-42-peptide, Tau, p-Thr181 Tau, and p-Ser396 Tau (compared to controls), which provided a high predictability of disease development in the preclinical stage [247].